サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1559666

男性性腺機能低下症の世界市場

Male Hypogonadism

出版日
ページ情報
英文 197 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
男性性腺機能低下症の世界市場
出版日: 2024年09月24日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

男性性腺機能低下症の世界市場は2030年までに61億米ドルに達する見込み

2023年に43億米ドルと推定される男性性腺機能低下症の世界市場は、分析期間2023-2030年にCAGR 5.0％で成長し、2030年には61億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるテストステロン補充療法は、CAGR 4.9%を記録し、分析期間終了時には35億米ドルに達すると予測されます。ゴナドトロピン＆ゴナドトロピン放出ホルモン療法分野の成長率は、分析期間中CAGR 5.3％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 4.8％で成長予測

米国の男性性腺機能低下症市場は、2023年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 4.8％を牽引し、2030年には予測市場規模9億6,250万米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.5％と4.3％と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の男性性腺機能低下症市場- 主要動向と促進要因まとめ

男性性腺機能低下症とは何か、なぜ早期診断が重要なのか？

男性性腺機能低下症は、テストステロンレベルの低下を特徴とする病状であり、性欲減退、疲労、筋力低下、気分障害などの様々な症状を引き起こします。この病態は、加齢、遺伝的要因、または精巣や下垂体に影響を及ぼす病状によって生じる可能性があります。男性性腺機能低下症の早期診断は、症状を管理し、骨粗鬆症、心血管疾患、不妊症などの長期合併症を予防するために不可欠です。世界の高齢化と男性のホルモンバランスの乱れに対する意識の高まりに伴い、効果的な治療と診断ツールに対する需要が大幅に高まっており、性腺機能低下症の早期発見と適切な管理の重要性が浮き彫りになっています。

ホルモン補充療法の進歩は男性性腺機能低下症治療をどのように形成しているか？

男性性腺機能低下症の治療は、テストステロンレベルを健康な範囲に回復させるホルモン補充療法（HRT）の開発により、大きく進歩しました。テストステロン補充療法（TRT）は、ジェル、注射、パッチなどさまざまな形で利用でき、性腺機能低下症の治療の要となっています。これらの治療法は、症状を緩和するだけでなく、テストステロン欠乏症に伴う長期的な健康問題のリスクを軽減するのにも役立ちます。投与回数が少なくて済む新しい長時間作用型製剤は、その利便性と安定したテストステロンレベルを維持する能力により、人気を集めています。さらに、個別化医療の進歩により、ヘルスケアプロバイダーが個々のニーズに合わせて治療を行うことが可能になり、患者の転帰と満足度が向上しています。

男性性腺機能低下症の管理にはどのような課題がありますか？

男性性腺機能低下症の治療には、特に患者が適切かつタイムリーな治療を受けられるようにする上で、いくつかの課題があります。課題の一つは、多くの男性がテストステロン欠乏症状を加齢のせいとし、医師の診察を受けようとしないため、この疾患が過小診断されていることです。さらに、心血管イベントのリスク増加や前立腺の問題など、長期的なテストステロン療法の潜在的な副作用は、患者と臨床医の双方に懸念を抱かせています。このようなリスクに対しては、慎重なモニタリングと個別の治療計画が必要です。テストステロン補充療法は高額であり、保険適用も様々であるため、治療へのアクセスにも課題があります。さらに、治療へのアドヒアランスは、特に治療を定期的に行う必要性から、依然として懸念事項です。

男性性腺機能低下症市場の成長はいくつかの要因によってもたらされる

男性性腺機能低下症市場の成長は、高齢化による有病率の上昇、男性のホルモン健康に対する意識の高まり、テストステロン補充療法の進歩など、いくつかの要因によって牽引されています。診断ツールの改善に伴い、より多くの男性が早期に診断されるようになり、効果的な治療に対する需要が高まっています。長時間作用型注射剤や経皮パッチなどのドラッグデリバリーシステムにおける技術革新は、患者のコンプライアンスと治療成績を向上させています。さらに、男性の健康への関心の高まりと遠隔医療サービスの利用可能性の増加が、患者が診断や治療を受けやすくしており、市場の拡大に寄与しています。

調査対象企業の例（注目の47社）

  • Bayer AG
  • TesoRx Pharma LLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13151

Global Male Hypogonadism Market to Reach US$6.1 Billion by 2030

The global market for Male Hypogonadism estimated at US$4.3 Billion in the year 2023, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$962.5 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Male Hypogonadism Market - Key Trends & Drivers Summarized

What Is Male Hypogonadism and Why Is Early Diagnosis Important?

Male hypogonadism is a medical condition characterized by low testosterone levels, leading to a range of symptoms such as reduced libido, fatigue, muscle loss, and mood disturbances. This condition can result from aging, genetic factors, or medical conditions that affect the testes or pituitary gland. Early diagnosis of male hypogonadism is essential for managing symptoms and preventing long-term complications such as osteoporosis, cardiovascular disease, and infertility. With the global aging population and increased awareness of hormonal imbalances in men, the demand for effective treatments and diagnostic tools has risen substantially, highlighting the importance of early detection and proper management of hypogonadism.

How Are Advances in Hormone Replacement Therapy Shaping Male Hypogonadism Treatment?

The treatment of male hypogonadism has advanced significantly with the development of hormone replacement therapies (HRT) that restore testosterone levels to a healthy range. Testosterone replacement therapy (TRT), available in various forms such as gels, injections, and patches, has become the cornerstone of treatment for hypogonadism. These therapies not only alleviate symptoms but also help reduce the risk of long-term health issues associated with testosterone deficiency. Newer, long-acting formulations that require less frequent administration are gaining popularity due to their convenience and ability to maintain stable testosterone levels. Additionally, advancements in personalized medicine are enabling healthcare providers to tailor treatments to individual needs, improving patient outcomes and satisfaction.

What Challenges Exist in Managing Male Hypogonadism?

Managing male hypogonadism presents several challenges, particularly in ensuring that patients receive appropriate and timely treatment. One challenge is the underdiagnosis of the condition, as many men may attribute symptoms of testosterone deficiency to aging and fail to seek medical attention. Moreover, the potential side effects of long-term testosterone therapy, such as increased risk of cardiovascular events and prostate issues, have raised concerns among both patients and clinicians. These risks necessitate careful monitoring and individualized treatment plans. Another challenge lies in access to care, as testosterone replacement therapies can be costly, and insurance coverage may vary. Additionally, adherence to therapy remains a concern, particularly with the need for regular administration of treatments.

Growth in the Male Hypogonadism Market Is Driven by Several Factors

The growth in the male hypogonadism market is driven by several factors, including the rising prevalence of the condition due to aging populations, increased awareness of hormonal health in men, and advancements in testosterone replacement therapies. As diagnostic tools improve, more men are being diagnosed earlier, leading to greater demand for effective treatments. Technological innovations in drug delivery systems, such as long-acting injectables and transdermal patches, are enhancing patient compliance and outcomes. Furthermore, the growing focus on men’s health and the increasing availability of telemedicine services are making it easier for patients to seek diagnosis and treatment, contributing to the market's expansion.

Select Competitors (Total 47 Featured) -

  • Bayer AG
  • TesoRx Pharma LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Male Hypogonadism - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Testosterone Deficiency Drives Growth in Male Hypogonadism Market
    • Technological Advancements in Hormone Replacement Therapies Propel Adoption
    • Growing Awareness of Male Hormonal Health Expands Addressable Market for Hypogonadism Treatments
    • Increased Focus on Mens Health Issues Strengthens Business Case for Hypogonadism Diagnosis
    • Rising Demand for Non-invasive Treatments Spurs Growth in Alternative Therapy Solutions
    • Technological Innovations in Testosterone Delivery Systems Accelerate Market Growth
    • Growing Use of Telemedicine Platforms Expands Access to Male Hypogonadism Treatment
    • Increasing Availability of Personalized Medicine Options Drives Adoption of Targeted Therapies
    • Improved Diagnostic Tools for Hormonal Imbalance Propel Demand for Early Detection
    • Rising Focus on Patient-centric Treatment Models Expands Opportunities for Customized Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Male Hypogonadism Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Delivery Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pituitary Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Klinefelters Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Kallmann Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Disorder Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • CHINA
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030

IV. COMPETITION